Lipid/Metabolic
Lifestyle-based diabetes prevention seen to endure for at least a decade
Oct 30, 2009 10:00 EDT
The protective effects of diet modification, exercise, and other lifestyle changes against new-onset diabetes showcased in the three-year Diabetes Prevention Program continued out to 10 years in a follow-up analysis.

Bethesda, MD - A number of prospective studies have shown that behavioral and lifestyle interventions can provide lasting protection against new type 2 diabetes in people at increased risk, but the question remains: For how long?

What might be the longest follow-up yet of patients from such a randomized controlled trial comes this week from the Diabetes Prevention Program (DPP) research group, which saw protective effects of both lifestyle intervention and treatment with metformin last as long as 10 years [1].Read full article »

Inside: Lipid/Metabolic
Accredited educational programs, supported by industry, developed by theheart.org

More
Lipid/Metabolic
Reducing CV Risk: What Add-On Therapies Do You Use?
13 COMMENTS - Jan 27, 2009 15:53 EST
Reducing CV Risk: What Add-On Therapies Do You Use? Click to take the survey and compare answers. The results will help us create future CME programming
More
Lipid/Metabolic
What happened at AHA 2008?: The Baylor College of Medicine Perspective
Dec 11, 2008 12:00 EST
Join Drs Ballantyne and Nambi as they discuss the Jupiter Trial and what was hot at AHA 2008 in lipids and prevention.
 
Medscape Medical News
Low-cholesterol/cancer studies should "dispel lingering doubts" of causal link
Nov 5, 2009 14:15 EST
Two new papers should help put to rest concerns that low serum cholesterol levels may increase cancer risk.
Lipid/Metabolic
Not all metabolic syndrome is created equal: Framingham Offspring analysis
Nov 5, 2009 11:45 EST
The syndrome (defined by ATP III criteria) can predict increased cardiovascular and mortality risk or not, depending on which three of five risk factors contributed to the diagnosis, a cohort study suggests; its investigators caution that their observations are only preliminary.
Interventional/Surgery
VELETI in print: Plaque sealing of SVGs a strategy "ahead of its time"?
Nov 4, 2009 15:30 EST
The imaging study was the first to show that stenting a non-flow-limiting stenosis of an SVG may help slow or halt the accelerated atherosclerosis that takes place in these vessels. An accompanying editorial cautions that the study does little more than "infer a trend toward anatomic benefit."
Hypertension
Adding fuel to the J-curve fire; debate is reignited
2 COMMENTS - Nov 4, 2009 14:30 EST
More discussion about the J-curve in hypertension is published this week; one expert believes the undue attention being paid to this subject might discourage doctors from treating high blood pressure aggressively.
Imaging
CAC scoring plus SPECT provide long and short view of cardiac risk
6 COMMENTS - Nov 3, 2009 17:00 EST
UPDATED // An 1126-patient trial shows that SPECT and CAC scoring imaging tests are independent and complementary predictors of short- and long-term cardiac risk, respectively.
heartbriefs
FDA expands exenatide use; warns of renal-failure risk
Nov 3, 2009 13:15 EST
The FDA has issued a warning about exenatide the same day the agency approved its first-line use along with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Heart failure
CORONA analysis reopens door for statins in heart failure
Nov 3, 2009 10:45 EST
Statins for heart failure? After they failed to show much effect in two large randomized trials? Yes—maybe; at least in patients with ischemic heart failure who start the drugs early enough, suggests a post hoc analysis based on one of the trials.
Imaging
Imaging study shows plaque regression with niacin vs placebo
15 COMMENTS - Oct 30, 2009 16:00 EDT
Just weeks before ARBITER-HALTS 6 results come out at AHA 2009, an MRI study suggests that niacin is better than placebo in statin-treated patients with low HDL, at least for reducing carotid wall area. Experts say they'd also like to see insights into niacin effects on lipid-rich plaque volumes—the more commonly seen end point with MRI.
heartbriefs
Combination drugs for weight loss
2 COMMENTS - Oct 29, 2009 15:30 EDT
Two studies presented this week have shown positive effects on weight loss using a combination of agents.
Medscape Medical News
CRP predicts mortality and MI, but not stroke
Oct 29, 2009 12:00 EDT
A new analysis from the Northern Manhattan Study finds that high-sensitivity C-reactive protein was modestly associated with mortality and MI but not ischemic stroke in this multiethnic population, suggesting the predictive value may depend on other factors.
Acute Coronary Syndromes
Sex differences in changing MI prevalence, mortality challenge conventional wisdom
Oct 29, 2009 10:30 EDT
Two well-known observational registries highlight such changes in women and men over a decade or more: Do women younger than 55 still have an advantage over men in the same age group?
View all »
Editorial Programs
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Bob Harrington
Nov 6, 2009 09:50 EST
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
Editorial series
Clinical research: Comparing regulatory pathways in US and UK
Oct 30, 2009 12:35 EDT
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Peter Sleight
2 COMMENTS - Oct 13, 2009 10:15 EDT
With the ISIS-1 trial, Dr Peter Sleight and his team at Oxford changed the approach to cardiovascular research. Join Dr Robert Califf as he talks to Dr Sleight about his journey from London to San Francisco to Oxford and finally to Italy, where he discovered the music of the heart.
button
Previews
View all CME programs >>
Resource center
LIPID/METABOLIC
A venue for information, slides, articles, tools, and support material for physicians and healthcare providers.
Poll
Do the latest postmarketing surveillance data reassure you about the risk of cancer with ezetimibe?
See: Michael O'Riordan. FDA postmarketing surveillance data show no cancer risk with ezetimibe.
Yes
No

Vote
View all »
Info from Industry
Promotional educational programs